查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1308691

到 2030 年數字治療市場預測 - 按類型、服務類型、購買模式、銷售渠道（B2C、B2B）、最終用戶和地區進行的全球分析

Digital Therapeutics Market Forecasts to 2030 - Global Analysis By Type, Service Type, Purchase Mode, Sales Channel (Business-to-Consumer and Business-to-Business ), End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球數字治療市場規模將達到 66.8 億美元，預測期內復合年增長率為 20.9%，到 2030 年將達到 252.4 億美元，預計將達到美元。

數字療法 (DTx) 使用基於證據、經過臨床評估的軟件和設備直接向患者提供醫療干預措施，以治療、管理和預防各種疾病和病症。 例如，數字療法可以幫助患者自我管理症狀，改善生活質量和其他臨床終點。 通過智能手機、移動設備和類似方式提供治療，這些數字方式可以幫助縮小醫療保健方面的差距。

根據國際糖尿病聯合會的數據，到 2021 年，全球 20-79 歲的糖尿病患者人數將從 2017 年的 4.25 億增加到 5.37 億。 預計到 2030 年，這一數字將達到 6.43 億。

市場動態：

驅動程序

可預防的慢性疾病的患病率增加

慢性病的高患病率和發病率是世界各地醫療保健系統的主要關注點。 慢性病患者的治療是一項重大挑戰，因為心身和心理生理因素經常影響這些患者。 慢性病通常具有高度的不確定性，要求患者改變自己的行為，作為新的自我保健生活方式的一部分。 此外，許多慢性疾病和病症是進行性的，其患病率隨著年齡的增長而增加。 因此，隨著世界人口老齡化的顯著增加，慢性病的數量預計將進一步增加。

限制

患者數據隱私問題

在許多國家，各種健康應用程序沒有得到適當的批准，導致人們對產品和數據質量、對治療決策的信任、患者隱私、安全性和負責任地使用數據的擔憂。 數字治療提供者可以訪問患者信息，但禁止與不參與該患者護理的任何人共享該信息。 然而，使用數字工具進行數據整合會使患者數據面臨被與患者護理計劃無關的醫療保健專業人員訪問的風險。

機會

製造商的戰略舉措

戰略舉措的實施可以為公司最重要的增長和擴張項目提供支持。 公司通常具備有效管理日常運營的能力，但新的戰略舉措往往是涉及多個工作流程的複雜項目。 我們的團隊巧妙地支持與綠地和合併後整合相關的獨特而復雜的任務流程，幫助客戶照常專注於業務。

威脅

患者不願接受數字化治療

提高數字治療的採用率和建立信任是數字治療提供商面臨的主要威脅。 老年人和服務不足的人群最容易感染疾病，患病率也最高，但由於技術素養水平較低，他們最不可能使用數字治療產品。 此外，數字治療可以觀察到多少行為改變的限制仍有待確定。

COVID-19 的影響：

由於人們對數字健康價值的認識不斷增強、精神疾病患病率上升以及藥物濫用率上升，預計 COVID-19 大流行將對全球數字治療市場產生積極影響。 此外，由於大流行迫使人們呆在家裡，我們看到體力活動減少、生活方式選擇增多、壓力水平升高，所有這些都導致了慢性病的流行。 因此，DTx 硬件和軟件在全球範圍內的需求量很大。 此外，由於最近放寬了對基於 DTX 的療法的監管審批，市場正在擴大。

疾病管理和治療 DTx 細分市場將在預測期內成為最大的細分市場：

疾病管理和治療 DTx 領域預計將在預測期內佔據最大的市場份額。 在此背景下，慢性病患病率不斷上升，疾病管理數字化治療解決方案的價格可承受，數字化治療的投資不斷增加，醫療成本的經濟負擔日益沉重，同時還需要降低成本。

企業對企業 (B2B) 細分市場預計在預測期內復合年增長率最高：

企業對企業 (B2B) 細分市場正以市場上最高的複合年增長率增長。 這是由於提供者、付款人和雇主對數字療法的好處越來越警惕，以及製藥公司將數字療法與其藥品相結合的趨勢。

份額最大的地區：

預計北美將在整個預測期內主導市場。 患有慢性疾病和藥物濫用障礙等精神疾病的患者數量不斷增加，是該區域市場佔據主導地位的原因。 此外，由於主要公司之間有更多的合作夥伴關係和協議來專注於這些產品的研發，預計該地區也將增加這些設備的採用。

複合年增長率最高的地區：

由於越來越多地採用先進技術產品和有利的政府政策，預計亞太地區的複合年增長率最高。 醫療保健 IT 系統的需求量很大，因為它們可以有效地管理醫院的臨床、財務和行政方面。 此外，廉價的移動設備和互聯網的廣泛使用預計將增加對這些產品的需求，刺激區域市場的擴張。

主要進展：

2023年1月，Lupin Limited的全資子公司Lupin宣布推出其治療解決方案LYFE。 LYFE 是印度唯一基於證據的整體心臟護理計劃，可顯著降低心髒病發作風險並改善心髒病患者的生命體徵和生活質量。

2022 年 10 月，Fitbit Health Solutions 宣布與 Pretaa 建立合作夥伴關係。 通過將健康和活動數據納入 Pretaa 的藥物濫用康復應用程序，我們的目標是改善與藥物濫用作鬥爭的美國人及其家人的治療結果。

2022 年 8 月，Akili Inc.（一家針對多動症兒童的視頻遊戲類數字治療設備製造商）宣布與特殊目的收購公司 Social Capital Suvretta Holdings Corp. 合併。

報告內容

  • 區域和國家級細分市場的市場份額評估
  • 給新進入者的戰略建議
  • 2021 年、2022 年、2023 年、2026 年和 2030 年的綜合市場數據
  • 市場趨勢（驅動因素、限制因素、機遇、威脅、挑戰、投資機會、建議）
  • 根據市場預測提出關鍵業務領域的戰略建議
  • 競爭格局繪製主要共同趨勢
  • 公司簡介，包括詳細的戰略、財務狀況和最新發展
  • 反映最新技術進步的供應鏈趨勢

免費定制服務：

訂閱此報告的客戶將獲得以下免費自定義選項之一：

  • 公司簡介
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 主要公司的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家/地區的市場估計/預測/複合年增長率（注：基於可行性檢查）
  • 競爭基準測試
    • 根據產品組合、地域分佈和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 執行摘要
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究來源
    • 二手研究來源
    • 先決條件

第三章市場趨勢分析

  • 驅動程序
  • 制約因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新冠肺炎 (COVID-19) 的影響

第 4 章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間存在敵對關係

第 5 章全球數字治療市場：按類型

  • 疾病管理/治療 DTx
  • 疾病預防DTx

第 6 章全球數字治療市場：按服務類型

  • 解決方案/軟件
  • 設備
  • 服務
  • 硬件

第 7 章全球數字治療市場：按購買類型

  • 個人購買
  • 集團採購組織

第 8 章全球數字治療市場：按分銷渠道劃分

  • 企業對消費者 (B2C)
    • 病人
    • 看護者
  • B2B（B2B）
    • 付款人
    • 醫療保健提供者
    • 雇主
    • 製藥公司
    • 其他企業對企業交易 (B2B)

第 9 章全球數字治療市場：按最終用戶劃分

  • 預防
    • 糖尿病前期
    • 肥胖
    • 營養管理
    • 生活方式管理
    • 其他預防措施
  • 治療/護理
    • 糖尿病
    • 中樞神經系統疾病
      • 心理健康障礙
      • 其他中樞神經系統疾病
    • 慢性呼吸系統疾病
    • 肌肉骨骼疾病
    • 心血管疾病
    • 禁止吸煙
    • 藥物依從性
    • 消化系統疾病
    • 藥物使用和成癮管理
    • 康復與患者護理
    • 其他治療/護理相關應用

第 10 章全球數字治療市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 亞太地區其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東和非洲地區

第 11 章主要進展

  • 合同、合作夥伴關係、聯盟和合資企業
  • 收購與合併
  • 推出新產品
  • 業務擴展
  • 其他關鍵策略

第12章公司簡介

  • 2Morrow, Inc
  • Akili Interactive Labs, Inc.
  • BigHealth
  • Canary Health Inc.
  • DarioHealth Corp.
  • Dthera Sciences
  • Fitbit LLC
  • GAIA AG
  • HYGIEIA
  • Limbix Health, Inc.
  • Livongo Health, Inc.
  • Mango Health Inc.
  • Medtronic Plc.
  • Noom, Inc.
  • Omada Health, Inc.
  • Pear Therapeutics, Inc.
  • Propeller Health（ResMed）
  • Voluntis, Inc.
  • Welldoc, Inc.
Product Code: SMRC23391

According to Stratistics MRC, the Global Digital Therapeutics Market is accounted for $6.68 billion in 2023 and is expected to reach $25.24 billion by 2030 growing at a CAGR of 20.9% during the forecast period. In order to treat, manage, and prevent a wide range of diseases and disorders, digital therapeutics (DTx) delivers medical interventions directly to patients using evidence-based, clinically evaluated software and devices. Digital therapeutics, for instance, can assist patients in managing their symptoms on their own, enhancing their quality of life and other clinical endpoints. By offering therapeutics through smartphones, mobile devices, and comparable modalities, these digital modalities help to reduce the gaps in healthcare.

According to the International Diabetes Federation, globally, the number of people with diabetes aged 20-79 reached 537 million in 2021 from 425 million in 2017. This number is further estimated to reach 643 million by 2030.

Market Dynamics:

Driver:

Growing incidence of preventable chronic diseases

The high prevalence and incidence rate of chronic diseases is a major concern for healthcare systems across the globe. The treatment of patients with chronic diseases is a significant challenge, as psychosomatic or bio psychic factors very often influence these patients. As chronic diseases are often associated with high levels of uncertainty, patients need to change their behavior as part of a new self-care lifestyle. Furthermore, many chronic disorders and conditions are progressive, and their incidence increases with age. As a result, with significant growth in the global geriatric population, chronic disorders are expected to rise further in the coming years.

Restraint:

Patient data privacy concerns

In many countries, various health apps are deprived of appropriate approvals, leading to concerns of product & data quality, reliability in treatment decisions, patient privacy, security, and the responsible use of data. Digital therapeutics providers have access to patient information and are forbidden from sharing the information with anyone not involved in treating that patient. However, with the integration of data using digital tools, the patient's data is at risk of being accessed by any healthcare professional not related to the patient's treatment program.

Opportunity:

Strategic initiatives by manufacturers

Strategic initiatives practice supports companies undertaking the most important growth or expansion projects. While organizations are normally well-geared to manage the day-to-day aspects of business efficiently, major new strategic initiatives tend to be complex projects with multiple workstreams involved. The team helps clients maintain focus on business-as-usual functions by dexterously supporting the unique and complex task flows that accompany Greenfield integration or post-merger integration.

Threat:

Reluctance among patients to adopt digital therapeutics

Motivating people to use digital therapeutics and building their confidence is a major threat faced by digital therapeutics providers. While older and underserved populations show maximum susceptibility to diseases and the highest occurrence rates, they are the least likely to use digital therapeutics products due to low technology literacy levels. Furthermore, the limit of how much behavioural change will be observed with digital therapeutics is still undefined.

COVID-19 Impact:

The COVID-19 pandemic is anticipated to have a positive effect on the global market for digital therapeutics due to increased awareness of the value of digital health, an increase in the prevalence of mental illness, and a rise in the rate of drug abuse. Additionally, because people were forced to stay at home due to the pandemic, there was a decrease in physical activity, an increase in unhealthy lifestyle choices, and a rise in stress levels, all of which contributed to the prevalence of chronic diseases. As a result, DTx hardware and software are in greater demand all over the world. Additionally, the market is growing as a result of recent regulatory approvals for treatments based on DTX being more relaxed.

The disease management and treatment DTx segment is expected to be the largest during the forecast period:

Over the forecast period, it is anticipated that the disease management and treatment DTx segment will hold the largest market share. This is attributed to the rise in chronic disease prevalence, the availability of affordable digital therapeutic solutions for disease management, rising investments in digital therapeutics, and the need to reduce healthcare costs due to the rising economic burden of healthcare costs.

The business-to-business (B2B) segment is expected to have the highest CAGR during the forecast period:

The business-to-business (B2B) segment is growing at the highest CAGR in the market. This is attributed to increasing alertness among providers, payers, and employers about the benefits of digital therapeutics and the inclination of pharmaceutical companies to integrate digital therapeutics with their drug products.

Region with largest share:

Throughout the forecast period, North America is anticipated to rule the market. The increasing prevalence of patients with chronic illnesses and mental health conditions, such as substance use disorders, is responsible for the dominance of this regional market. Moreover, the introduction of these devices in the region is also anticipated to increase as a result of an increase in collaborations and agreements among the major players to concentrate on the research and development of these products.

Region with highest CAGR:

Due to the increased adoption of technologically advanced products and advantageous government policies, the Asia-Pacific market is estimated to witness the highest compound annual growth rate. The need for healthcare IT systems has been growing as they make it possible to manage hospitals' clinical, financial, and administrative aspects effectively. Additionally, it is anticipated that the widespread use of inexpensive mobile devices and the internet will increase demand for these products, spurring regional market expansion.

Key players in the market

Some of the key players profiled in the Digital Therapeutics Market include 2Morrow, Inc, Akili Interactive Labs, Inc., BigHealth , Canary Health Inc., DarioHealth Corp., Dthera Sciences, Fitbit LLC, GAIA AG, HYGIEIA, Limbix Health, Inc. , Livongo Health, Inc., Mango Health Inc., Medtronic Plc., Noom, Inc., Omada Health, Inc., Pear Therapeutics, Inc., Propeller Health (ResMed), Voluntis, Inc. and Welldoc, Inc.

Key Developments:

In January 2023, Lupin, a wholly-owned subsidiary of Lupin Limited, announced the launch of its therapeutics solution, LYFE. LYFE is India's only evidence-based holistic heart care programme that significantly reduces the risk of a heart attack and improves vitals and quality of life for cardiac patients.

In October 2022, Fitbit Health Solutions introduced a partnership with Pretaa that seeks to improve outcomes for Americans and their families affected by substance abuse by introducing health and activity data in Pretaa's substance abuse recovery app.

In August 2022, Akili Inc., the maker of a video game-like digital therapeutic for children with ADHD, announced the merger with a special-purpose acquisition company Social Capital Suvretta Holdings Corp.

Types Covered:

  • Disease Management and Treatment DTx
  • Disease Prevention DTx

Service Types Covered:

  • Solutions/Software
  • Device
  • Service
  • Hardware

Purchase Modes Covered:

  • Individual
  • Group Purchase Organization

Sales Channels Covered:

  • Business-to-Consumer (B2C)
  • Business-to-Business (B2B)

End Users Covered:

  • Preventive
  • Treatment/Care-related

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026 and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Digital Therapeutics Market, By Type

  • 5.1 Introduction
  • 5.2 Disease Management and Treatment DTx
  • 5.3 Disease Prevention DTx

6 Global Digital Therapeutics Market, By Service Type

  • 6.1 Introduction
  • 6.2 Solutions/Software
  • 6.3 Device
  • 6.4 Service
  • 6.5 Hardware

7 Global Digital Therapeutics Market, By Purchase Mode

  • 7.1 Introduction
  • 7.2 Individual
  • 7.3 Group Purchase Organization

8 Global Digital Therapeutics Market, By Sales Channel

  • 8.1 Introduction
  • 8.2 Business-to-Consumer (B2C)
    • 8.2.1 Patients
    • 8.2.2 Caregivers
  • 8.3 Business-to-Business (B2B)
    • 8.3.1 Payers
    • 8.3.2 Healthcare Provider
    • 8.3.3 Employers
    • 8.3.4 Pharmaceutical Companies
    • 8.3.5 Other Business-to-Business (B2B)

9 Global Digital Therapeutics Market, By End User

  • 9.1 Introduction
  • 9.2 Preventive
    • 9.2.1 Prediabetes
    • 9.2.2 Obesity
    • 9.2.3 Nutrition
    • 9.2.4 Lifestyle Management
    • 9.2.5 Other Preventive Applications
  • 9.3 Treatment/Care-related
    • 9.3.1 Diabetes
    • 9.3.2 CNS Disorders
      • 9.3.2.1 Mental Health Disorder
      • 9.3.2.2 Other CNS Disorders
    • 9.3.3 Chronic Respiratory Disorders
    • 9.3.4 Musculoskeletal Disorders
    • 9.3.5 Cardiovascular Diseases
    • 9.3.6 Smoking Cessation
    • 9.3.7 Medication Adherence
    • 9.3.8 Gastrointestinal Disorders
    • 9.3.9 Substance Use & Addiction Management
    • 9.3.10 Rehabilitation & Patient Care
    • 9.3.11 Other Treatment/Care-related Applications

10 Global Digital Therapeutics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 2Morrow, Inc
  • 12.2 Akili Interactive Labs, Inc.
  • 12.3 BigHealth
  • 12.4 Canary Health Inc.
  • 12.5 DarioHealth Corp.
  • 12.6 Dthera Sciences
  • 12.7 Fitbit LLC
  • 12.8 GAIA AG
  • 12.9 HYGIEIA
  • 12.10 Limbix Health, Inc.
  • 12.11 Livongo Health, Inc.
  • 12.12 Mango Health Inc.
  • 12.13 Medtronic Plc.
  • 12.14 Noom, Inc.
  • 12.15 Omada Health, Inc.
  • 12.16 Pear Therapeutics, Inc.
  • 12.17 Propeller Health (ResMed)
  • 12.18 Voluntis, Inc.
  • 12.19 Welldoc, Inc.

List of Tables

  • Table 1 Global Digital Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Digital Therapeutics Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Digital Therapeutics Market Outlook, By Disease Management and Treatment DTx (2021-2030) ($MN)
  • Table 4 Global Digital Therapeutics Market Outlook, By Disease Prevention DTx (2021-2030) ($MN)
  • Table 5 Global Digital Therapeutics Market Outlook, By Service Type (2021-2030) ($MN)
  • Table 6 Global Digital Therapeutics Market Outlook, By Solutions/Software (2021-2030) ($MN)
  • Table 7 Global Digital Therapeutics Market Outlook, By Device (2021-2030) ($MN)
  • Table 8 Global Digital Therapeutics Market Outlook, By Service (2021-2030) ($MN)
  • Table 9 Global Digital Therapeutics Market Outlook, By Hardware (2021-2030) ($MN)
  • Table 10 Global Digital Therapeutics Market Outlook, By Purchase Mode (2021-2030) ($MN)
  • Table 10 Global Digital Therapeutics Market Outlook, By Individual (2021-2030) ($MN)
  • Table 10 Global Digital Therapeutics Market Outlook, By Group Purchase Organization (2021-2030) ($MN)
  • Table 13 Global Digital Therapeutics Market Outlook, By Sales Channel (2021-2030) ($MN)
  • Table 14 Global Digital Therapeutics Market Outlook, By Business-to-Consumer (B2C) (2021-2030) ($MN)
  • Table 15 Global Digital Therapeutics Market Outlook, By Patients (2021-2030) ($MN)
  • Table 16 Global Digital Therapeutics Market Outlook, By Caregivers (2021-2030) ($MN)
  • Table 17 Global Digital Therapeutics Market Outlook, By Business-to-Business (B2B) (2021-2030) ($MN)
  • Table 18 Global Digital Therapeutics Market Outlook, By Payers (2021-2030) ($MN)
  • Table 19 Global Digital Therapeutics Market Outlook, By Healthcare Provider (2021-2030) ($MN)
  • Table 20 Global Digital Therapeutics Market Outlook, By Employers (2021-2030) ($MN)
  • Table 21 Global Digital Therapeutics Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 22 Global Digital Therapeutics Market Outlook, By Other Business-to-Business (B2B) (2021-2030) ($MN)
  • Table 23 Global Digital Therapeutics Market Outlook, By End User (2021-2030) ($MN)
  • Table 24 Global Digital Therapeutics Market Outlook, By Preventive (2021-2030) ($MN)
  • Table 25 Global Digital Therapeutics Market Outlook, By Prediabetes (2021-2030) ($MN)
  • Table 26 Global Digital Therapeutics Market Outlook, By Obesity (2021-2030) ($MN)
  • Table 27 Global Digital Therapeutics Market Outlook, By Nutrition (2021-2030) ($MN)
  • Table 28 Global Digital Therapeutics Market Outlook, By Lifestyle Management (2021-2030) ($MN)
  • Table 29 Global Digital Therapeutics Market Outlook, By Other Preventive Applications (2021-2030) ($MN)
  • Table 30 Global Digital Therapeutics Market Outlook, By Treatment/Care-related (2021-2030) ($MN)
  • Table 31 Global Digital Therapeutics Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 32 Global Digital Therapeutics Market Outlook, By CNS Disorders (2021-2030) ($MN)
  • Table 33 Global Digital Therapeutics Market Outlook, By Chronic Respiratory Disorders (2021-2030) ($MN)
  • Table 34 Global Digital Therapeutics Market Outlook, By Musculoskeletal Disorders (2021-2030) ($MN)
  • Table 35 Global Digital Therapeutics Market Outlook, By Cardiovascular Diseases (2021-2030) ($MN)
  • Table 36 Global Digital Therapeutics Market Outlook, By Smoking Cessation (2021-2030) ($MN)
  • Table 37 Global Digital Therapeutics Market Outlook, By Medication Adherence (2021-2030) ($MN)
  • Table 38 Global Digital Therapeutics Market Outlook, By Gastrointestinal Disorders (2021-2030) ($MN)
  • Table 39 Global Digital Therapeutics Market Outlook, By Substance Use & Addiction Management (2021-2030) ($MN)
  • Table 40 Global Digital Therapeutics Market Outlook, By Rehabilitation & Patient Care (2021-2030) ($MN)
  • Table 41 Global Digital Therapeutics Market Outlook, By Other Treatment/Care-related Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, Asia Pacific, South America and Middle East & Africa Regions are also represented in the same manner as above.